{"log_id": 3906811475029638079, "direction": 0, "words_result_num": 50, "words_result": [{"probability": {"variance": 0.00069, "average": 0.98913, "min": 0.878966}, "location": {"width": 547, "top": 183, "height": 31, "left": 209}, "words": "可以抑制由肿瘤释放的多种刺激因子引起的破骨细胞活动增强和骨钙释放"}, {"probability": {"variance": 0, "average": 0.999124, "min": 0.998692}, "location": {"width": 69, "top": 219, "height": 22, "left": 251}, "words": "毒理研究"}, {"probability": {"variance": 0.002198, "average": 0.989777, "min": 0.674004}, "location": {"width": 807, "top": 238, "height": 35, "left": 248}, "words": "遗传毒性:本品Ames细菌回复突变试验、中国仓鼠卵巢细胞染色体畸变试验、中国仓鼠基因突变试验和大"}, {"probability": {"variance": 1e-06, "average": 0.998333, "min": 0.99626}, "location": {"width": 190, "top": 276, "height": 27, "left": 209}, "words": "鼠微核试验结果均为阴性"}, {"probability": {"variance": 0.004116, "average": 0.978283, "min": 0.604317}, "location": {"width": 801, "top": 297, "height": 34, "left": 249}, "words": "生殖毒性:雌性大鼠从交配前15天至怀孕期结束皮下注射本品0.01、0.03或0.1mg/kg/日(AUC为人静脉注"}, {"probability": {"variance": 0.00123, "average": 0.985394, "min": 0.776036}, "location": {"width": 849, "top": 327, "height": 37, "left": 208}, "words": "射4mg时的07、0.2和1.2倍),高剂量组动物出现排卵抑制和受孕率下降。中剂量和高剂量组动物均出现胚胎植"}, {"probability": {"variance": 0.000264, "average": 0.992534, "min": 0.899511}, "location": {"width": 840, "top": 355, "height": 37, "left": 208}, "words": "入前丢失增加、植入胚胎数及活胎数减少,新生鼠的存活率下降。所有剂量组母鼠均出现难产及围生期死亡率增加"}, {"probability": {"variance": 1e-05, "average": 0.997961, "min": 0.985697}, "location": {"width": 769, "top": 386, "height": 34, "left": 208}, "words": "母鼠死亡的原因可能与药物抑制骨钙动员,导致围生期低血钙有关,这可能是双膦酸类药物共有的作用"}, {"probability": {"variance": 0.013116, "average": 0.95758, "min": 0.451863}, "location": {"width": 807, "top": 414, "height": 35, "left": 240}, "words": "雌性大鼠怀孕期间皮下注射本品0.10.2或0.4mg/kg/日(AUC为人静脉注射时4mg的12、2.4或4.8),中"}, {"probability": {"variance": 9.3e-05, "average": 0.994229, "min": 0.955824}, "location": {"width": 846, "top": 443, "height": 35, "left": 209}, "words": "高剂量组动物出现胚胎植入前或植入后丢失增加、活胎数减少、胎仔骨骼、内脏和外观畸形。高剂量组动物胎仔的"}, {"probability": {"variance": 0.000505, "average": 0.992051, "min": 0.86946}, "location": {"width": 846, "top": 472, "height": 36, "left": 208}, "words": "骨骼畸形表现为未骨化和骨化不全,骨骼增厚、弯曲或缩短等。高剂量组还可见晶状体缩小、小脑发育不全、肝小"}, {"probability": {"variance": 0.00249, "average": 0.985252, "min": 0.68161}, "location": {"width": 845, "top": 501, "height": 36, "left": 209}, "words": "叶缩小或缺失、肺叶变形、血管扩张、腭裂、水肿等毒性反应。低剂量组动物胎仔也出现骨骼畸形。本试验中高剂"}, {"probability": {"variance": 0.000937, "average": 0.992569, "min": 0.824615}, "location": {"width": 550, "top": 534, "height": 31, "left": 210}, "words": "量组母体动物出现体重和摄食量下降,提示试验已达到最高药物暴露水平"}, {"probability": {"variance": 0.001192, "average": 0.984105, "min": 0.813315}, "location": {"width": 805, "top": 560, "height": 34, "left": 250}, "words": "妊娠家兔皮下给予本品0.01、0.03、0.1mgkg/日(AUC小于或等于人静脉注射4mg时的0.5倍),未观察到"}, {"probability": {"variance": 0.000293, "average": 0.992981, "min": 0.882792}, "location": {"width": 845, "top": 589, "height": 35, "left": 209}, "words": "本品对胎仔的毒性。各用药组动物(按相对体表面折算,剂量大于或等于人静脉用药剂量4mg的0.05倍)均出现"}, {"probability": {"variance": 1.1e-05, "average": 0.99828, "min": 0.986787}, "location": {"width": 412, "top": 623, "height": 30, "left": 211}, "words": "母体死亡和流产,此现象可能与药物引起的低血钙有关"}, {"probability": {"variance": 0.007801, "average": 0.974374, "min": 0.364312}, "location": {"width": 804, "top": 649, "height": 33, "left": 251}, "words": "致癌性:采用小鼠和大鼠进行了常规终生致癌试验研究。小鼠经口给予本品0.10.5、2.0mgkg/日(按相对"}, {"probability": {"variance": 0.000738, "average": 0.989437, "min": 0.837864}, "location": {"width": 647, "top": 680, "height": 33, "left": 211}, "words": "体表面折算,剂量大于或等于人静脉用药剂量4mg的0.002倍)所有给药组动物 Hardc"}, {"probability": {"variance": 0.000441, "average": 0.985697, "min": 0.929701}, "location": {"width": 153, "top": 679, "height": 22, "left": 901}, "words": "副泪腺)腺癌的发生"}, {"probability": {"variance": 0.003409, "average": 0.980923, "min": 0.576495}, "location": {"width": 844, "top": 708, "height": 35, "left": 212}, "words": "率增加。大鼠经口给予本品0.1、0.5、2.0mg/kg/日(按相对体表面折算,剂量小于或等于人静脉用药剂量4mg的0.2"}, {"probability": {"variance": 0.01156, "average": 0.966373, "min": 0.59411}, "location": {"width": 215, "top": 745, "height": 25, "left": 210}, "words": "倍),未见肿瘤发生率的增加"}, {"probability": {"variance": 2.5e-05, "average": 0.996289, "min": 0.984408}, "location": {"width": 113, "top": 775, "height": 24, "left": 216}, "words": "【药代动力学】"}, {"probability": {"variance": 0, "average": 0.999339, "min": 0.998699}, "location": {"width": 37, "top": 806, "height": 21, "left": 271}, "words": "分布"}, {"probability": {"variance": 0.00021, "average": 0.993039, "min": 0.915224}, "location": {"width": 809, "top": 824, "height": 34, "left": 246}, "words": "64名癌症或骨转移患者静脉滴注单剂量或多剂量(28天4次)2、4、8或16mg,滴注时间5或15分钟,滴"}, {"probability": {"variance": 0.004821, "average": 0.979243, "min": 0.606071}, "location": {"width": 832, "top": 853, "height": 35, "left": 210}, "words": "注后血浆中唑来膦酸浓度的降低符合三相消除过程,滴注完毕迅速从峰浓度值下降,24小时后血药浓度不到Cn"}, {"probability": {"variance": 0.022936, "average": 0.935434, "min": 0.42679}, "location": {"width": 837, "top": 882, "height": 36, "left": 210}, "words": "的1%。最初两相的半衰期tia为0.24小时,t为1.87小时,唑来膦酸最终清除相的时间较长,在滴注后的2"}, {"probability": {"variance": 0.010372, "average": 0.969033, "min": 0.457736}, "location": {"width": 845, "top": 911, "height": 35, "left": 210}, "words": "28天内在血浆中仍保持很低的浓度,最终清除半衰期t1v为146小时,在给药剂量2-16mg范围内,血浆中药物浓"}, {"probability": {"variance": 0.002962, "average": 0.983717, "min": 0.619213}, "location": {"width": 848, "top": 940, "height": 37, "left": 209}, "words": "度时间曲线下面积(AUC1)与给药剂量呈正比。在3相中唑来膦酸的蓄积率均较低,其中2、3相相对于第1相"}, {"probability": {"variance": 0.017339, "average": 0.950403, "min": 0.354975}, "location": {"width": 846, "top": 970, "height": 37, "left": 210}, "words": "的平均AC2值比率分别为1.13±0.30和116±036。体内及体外试验表明唑来膦酸与人血细胞的亲和率低,与人"}, {"probability": {"variance": 0.000276, "average": 0.994761, "min": 0.91971}, "location": {"width": 359, "top": 1007, "height": 29, "left": 212}, "words": "血浆蛋白结合率大约为22%,结合率与浓度无关"}, {"probability": {"variance": 0, "average": 0.99945, "min": 0.99945}, "location": {"width": 30, "top": 1042, "height": 21, "left": 278}, "words": "谢"}, {"probability": {"variance": 0.00091, "average": 0.98832, "min": 0.821567}, "location": {"width": 790, "top": 1061, "height": 34, "left": 247}, "words": "体外试验表明唑来膦酸对人P450酶无抑制作用,唑来膦酸在体内不经过生物转化,主要以原形经肾脏排泄"}, {"probability": {"variance": 1.5e-05, "average": 0.996759, "min": 0.990229}, "location": {"width": 70, "top": 1099, "height": 24, "left": 250}, "words": "3、排泄"}, {"probability": {"variance": 0.004442, "average": 0.987112, "min": 0.521544}, "location": {"width": 804, "top": 1119, "height": 36, "left": 246}, "words": "64名患者在给予唑来膦酸24小时内尿液中平均回收率为39±16%,给药后第2日尿液中仅发现痕述量的药物"}, {"probability": {"variance": 0.002582, "average": 0.985526, "min": 0.67398}, "location": {"width": 844, "top": 1147, "height": 36, "left": 211}, "words": "给药0~24小时内尿液中累积排泄百分比率与药物的浓度无关,0~24小时内尿液中的药物回收达到平衡,推测"}, {"probability": {"variance": 0.001183, "average": 0.991789, "min": 0.755357}, "location": {"width": 841, "top": 1176, "height": 37, "left": 212}, "words": "药物先与骨结合,再缓慢释放进入全身循环,从而出现所观察到的血浆中长期含有很低浓度药物的现象。给药后0"}, {"probability": {"variance": 0.006328, "average": 0.970679, "min": 0.629419}, "location": {"width": 846, "top": 1207, "height": 36, "left": 211}, "words": "24小时内唑来膦酸的肾脏清除率为3.7±2.0Lh,唑来膦酸的清除率与剂量无关而取决于肌酐清除率。在一项研究"}, {"probability": {"variance": 0.008202, "average": 0.971457, "min": 0.485557}, "location": {"width": 661, "top": 1237, "height": 36, "left": 213}, "words": "中,将癌症及骨转移患者给于4mg唑来膦酸的滴注时间从5分钟(n=5)延长至15分钟"}, {"probability": {"variance": 0.000436, "average": 0.985134, "min": 0.934553}, "location": {"width": 116, "top": 1238, "height": 22, "left": 941}, "words": "结果滴完时唑来"}, {"probability": {"variance": 0.013324, "average": 0.938889, "min": 0.448604}, "location": {"width": 794, "top": 1266, "height": 36, "left": 212}, "words": "膦酸的浓度同比降低了34%(【平均值土SD]403±118 ng/ml vs264±86ng/m),AUC总值升高了10%(378士"}, {"probability": {"variance": 0.008471, "average": 0.924569, "min": 0.779972}, "location": {"width": 146, "top": 1309, "height": 20, "left": 214}, "words": " h/mlvs420±218ng"}, {"probability": {"variance": 8.3e-05, "average": 0.993109, "min": 0.972016}, "location": {"width": 221, "top": 1303, "height": 24, "left": 434}, "words": "AUC值的差异并无统计学意义"}, {"probability": {"variance": 0, "average": 0.999757, "min": 0.999565}, "location": {"width": 33, "top": 1337, "height": 22, "left": 280}, "words": "藏】"}, {"probability": {"variance": 0.011515, "average": 0.957892, "min": 0.654698}, "location": {"width": 158, "top": 1365, "height": 25, "left": 245}, "words": "遮光,密闭,在室温"}, {"probability": {"variance": 0.002662, "average": 0.973656, "min": 0.870472}, "location": {"width": 87, "top": 1363, "height": 23, "left": 507}, "words": "干燥处保存"}, {"probability": {"variance": 4e-06, "average": 0.998154, "min": 0.995354}, "location": {"width": 99, "top": 1396, "height": 23, "left": 216}, "words": "【包装】"}, {"probability": {"variance": 0.000914, "average": 0.983842, "min": 0.904665}, "location": {"width": 121, "top": 1426, "height": 22, "left": 249}, "words": "西林瓶,1瓶/盒"}, {"probability": {"variance": 0.002583, "average": 0.969243, "min": 0.881242}, "location": {"width": 87, "top": 1455, "height": 23, "left": 226}, "words": "有效期】"}, {"probability": {"variance": 4e-06, "average": 0.998237, "min": 0.99394}, "location": {"width": 97, "top": 1484, "height": 23, "left": 248}, "words": "暂定24个月"}, {"probability": {"variance": 6.9e-05, "average": 0.991305, "min": 0.979942}, "location": {"width": 81, "top": 1512, "height": 25, "left": 222}, "words": "【执行标准"}], "language": 3}